Table 1.
Theranostics polymeric and metal-based nanoplatforms under study for clinical applications in different cancers (according to clinicaltrials.gov and clinicaltrialsregister.eu).
| Product | Company | Clinical Phase | Therapeutic Modality | Diagnostic Modality | Proposed Indication | CT Identifier |
|---|---|---|---|---|---|---|
| CriPec® docetaxel | Cristal Therapeutics | Phase I | Docetaxel | PET (Zirconium-89) | Solid tumors | NCT03712423 |
| AGuIX® | NHTherAguix | Phase I | Radiation therapy | MRI (gadolinium-chelates) | Brain metastases | NCT02820454 |
| AGuIX® | NHTherAguix | Phase I | Radiation therapy or brachytherapy or chemotherapy (cisplatin) | MRI (gadolinium-chelates) | Gynecologic cancer | NCT03308604 |
| Iron oxide nanoparticles (SPIONs) | M.D. Anderson Cancer Center | Early Phase I | - | Ferumoxytol-based MRI | HNSCC | NCT01895829 |
| NBTXR3® | Nanobiotix | Phase I/II | Hafnium oxide nanoparticles (50 nm) | Radiation-stimulated technology (NanoX-Ray) via electron production | Multiple solid cancers, including head and neck cancer, rectal cancer, prostate cancer and breast cancer | NCT02805894 NCT03589339 NCT02901483 NCT02901483 NCT02465593 (Total of 5 active clinical trials) |
Abbreviations: ANZUP: Australian and New Zealand Urogenital and Prostate Cancer Trials Group. HNSCC: head and neck squamous cell carcinoma. MRI: magnetic resonance imaging. PET: positron emission tomography. SPION: superparamagnetic iron oxide nanoparticles.